Advanced Filters
noise

Chiba, Urayasu, Japan Clinical Trials

A listing of Chiba, Urayasu, Japan clinical trials actively recruiting patients volunteers.

Found 368 clinical trials

Study of AUBE00 in Patients With Solid Tumors

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 70 to 100.

18 years of age All Phase 1
M Makoto Ueno, M.D., Ph.D.

NCCH2006/MK010 Trial (FORTUNE Trial)

This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors harboring FGFR genetic alterations (including fusion, mutation, amplification).

20 years of age All Phase 2

Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure

The goal of this clinical trial is to verify that Non-Antithrombotic Therapy (NAPT) followed by Oral Anticoagulants (OAC) monotherapy for 45 days after Left Atrial Appendage Closure (LAAC) is non-inferior to Single Antiplatelet Therapy (SAPT) with aspirin during the period from randomization to the end of observational period (4 years …

years of age All Phase 4

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

18 years of age All Phase 3
H Hiroki Hara

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma

This is a Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects with Previously Treated Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma to compare the progression free survival (PFS) and overall survival (OS)

18 years of age All Phase 3

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.

18 years of age All Phase 2

A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee

To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients with osteoarthritis of the knee (OAK).

20 - 79 years of age All Phase 3
U US GSK Clinical Trials Call Center

A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors

Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking …

18 years of age All Phase 1/2

Study to ONO-4538 in Patients With Rhabdoid Tumor

Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

1 years of age All Phase 2

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.

18 years of age All Phase 1

Simplify language using AI